TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthocell Ltd ( (AU:OCC) ) has issued an announcement.
Orthocell Limited has issued 150,000 fully paid ordinary shares at $0.48 each following the exercise of unlisted options, complying with relevant sections of the Corporations Act 2001. This issuance reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the regenerative medicine sector, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in developing products for the repair of bone and soft tissue injuries. Their product portfolio includes collagen medical devices for tissue reconstruction in dental and orthopedic applications, with products like Striate+™ and Remplir™ cleared for use in multiple countries. The company is also advancing its tendon cell therapy in the US.
Average Trading Volume: 633,124
Technical Sentiment Signal: Buy
Current Market Cap: A$329.7M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.